KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Acquisitions & Divestments (2020 - 2025)

CRISPR Therapeutics AG's Change in Acquisitions & Divestments history spans 6 years, with the latest figure at -$710.6 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 290.5% year-over-year to -$710.6 million; the TTM value through Dec 2025 reached $702000.0, down 99.94%, while the annual FY2025 figure was $702000.0, 99.94% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was -$710.6 million at CRISPR Therapeutics AG, down from $214.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $419.7 million in Q3 2022 and bottomed at -$1.2 billion in Q4 2023.
  • The 5-year median for Change in Acquisitions & Divestments is $232.4 million (2022), against an average of $148.0 million.
  • The largest annual shift saw Change in Acquisitions & Divestments surged 194.21% in 2022 before it crashed 458.43% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $123.0 million in 2021, then soared by 164.25% to $325.1 million in 2022, then plummeted by 458.43% to -$1.2 billion in 2023, then skyrocketed by 132.01% to $373.0 million in 2024, then plummeted by 290.5% to -$710.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Change in Acquisitions & Divestments are -$710.6 million (Q4 2025), $214.9 million (Q3 2025), and $310.2 million (Q2 2025).